Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function

被引:0
作者
Cojutti, Pier Giorgio [1 ,2 ]
Ramos-Martin, Virginia [3 ]
Schiavon, Isabella [4 ]
Rossi, Paolo [4 ]
Baraldo, Massimo [1 ,2 ]
Hope, William [3 ]
Pea, Federico [1 ,2 ]
机构
[1] Santa Maria della Misericordia Univ Hosp Udine, Inst Clin Pharmacol, Udine, Italy
[2] Univ Udine, Dept Expt & Clin Med Sci, Udine, Italy
[3] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Antimicrobial Pharmacodynam & Therapeut, Liverpool, Merseyside, England
[4] Santa Maria della Misericordia Univ Hosp Udine, Div Internal Med 1, Udine, Italy
关键词
fluoroquinolones; personalized therapy; safety; efficacy; population pharmacokinetics; RESPIRATORY-TRACT INFECTIONS; COMMUNITY-ACQUIRED PNEUMONIA; INTRAVENOUS LEVOFLOXACIN; STREPTOCOCCUS-PNEUMONIAE; HEALTHY-VOLUNTEERS; ELDERLY-PATIENTS; 500; MG; FLUOROQUINOLONES; 750-MILLIGRAM; REGIMENS;
D O I
10.1128/AAC.02134-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A retrospective study was conducted in a large sample of acutely hospitalized older patients who underwent therapeutic drug monitoring during levofloxacin treatment. The aim was to assess the population pharmacokinetics (popPK) and pharmacodynamics of levofloxacin among older patients. PopPK and Monte Carlo simulation were performed to define the permissible doses in older patients according to various degrees of renal function. Classification and regression tree (CART) analysis was used to detect the cutoff 24-hour area under the concentration-time curve (AUC24)/MIC ratio that best correlated with the clinical outcome. The probability of target attainment (PTA) of this value was calculated against different pathogens. A total of 168 patients were included, and 330 trough and 239 peak concentrations were used for the popPK analysis. Creatinine clearance (CrCL) was the only covariate that improved the model fit (levofloxacin CL = 0.399 + 0.051 x CrCLCKD-EPI [creatinine clearance estimated by means of the chronic kidney disease epidemiology]). Drug doses ranged between 500 mg every 48 h and 500 mg every 12 h in relation to different renal functions. The identified cutoff AUC(24)/MIC ratio (>= 95.7) was the only covariate that correlated with a favorable clinical outcome in multivariate regression analysis (odds ratio [OR], 20.85; 95% confidence interval [CI], 1.56 to 186.73). PTAs were optimal (> 80%) against Escherichia coli and Haemophilus influenzae, borderline against Staphylococcus aureus, and suboptimal against Pseudomonas aeruginosa. The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of <= 0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk. Conversely, the addition of another active antimicrobial should be considered whenever treating infections caused by less susceptible pathogens.
引用
收藏
页数:11
相关论文
共 27 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   Levofloxacin - A review of its use as a high-dose, short-course treatment for bacterial infection [J].
Anderson, Vanessa R. ;
Perry, Caroline M. .
DRUGS, 2008, 68 (04) :535-565
[3]  
[Anonymous], 2016, Clinical Breakpoints
[4]   Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system [J].
Arabyat, Rasha M. ;
Raisch, Dennis W. ;
McKoy, June M. ;
Bennett, Charles L. .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (11) :1653-1660
[5]   Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? [J].
Bidell, Monique R. ;
Lodise, Thomas P. .
PHARMACOTHERAPY, 2016, 36 (06) :679-693
[6]  
Blondeau JM, 1999, CLIN THER, V21, P3
[7]   Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide [J].
Brendel, Karl ;
Comets, Emmanuelle ;
Laffont, Celine ;
Laveille, Christian ;
Mentre, France .
PHARMACEUTICAL RESEARCH, 2006, 23 (09) :2036-2049
[8]   Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis [J].
Cazzola, M ;
Matera, MG ;
Donnarumma, G ;
Tufano, MA ;
Sanduzzi, A ;
Marchetti, F ;
Blasi, F .
CHEST, 2005, 128 (04) :2093-2098
[9]   Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers [J].
Chien, SC ;
Wong, FA ;
Fowler, CL ;
Callery-D'Amico, SV ;
Williams, RR ;
Nayak, R ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :885-888
[10]   OPEN-LABEL CROSSOVER STUDY TO DETERMINE PHARMACOKINETICS AND PENETRATION OF 2 DOSE REGIMENS OF LEVOFLOXACIN INTO INFLAMMATORY FLUID [J].
CHILD, J ;
MORTIBOY, D ;
ANDREWS, JM ;
CHOW, AT ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2749-2751